UNICREDIT BANK/CALL/BIOGEN IDEC/320/0.1/19.03.25 | Market Closed - BOERSE MUENCHEN 01:10:41 01/06/2024 am IST | ||
| 0.81 EUR | +15.71% |
|
| 1 month | +62.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.81 | +15.71% |
| 30/24/30 | 0.7 | +9.37% |
| 29/24/29 | 0.64 | -7.25% |
| 28/24/28 | 0.69 | -4.17% |
| 27/24/27 | 0.72 | -.--% |
Real-time BOERSE MUENCHEN
Last update May 01, 2024 at 01:10 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD4FKS |
| ISIN | DE000HD4FKS9 |
| Date issued | 08/04/2024 |
| Strike | 320 $ |
| Maturity | 19/03/2025 (292 Days) |
| Parity | 10 : 1 |
| Emission price | 0.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.92 € |
|---|---|
| Lowest since issue | 0.31 € |
| Spread | 0.02 € |
| Spread % | 2.41% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Warrants
- Warrant
